Day: June 10, 2024

Galimedix Therapeutics Establishes Scientific Advisory Board of Renowned Retina Experts as Company Prepares to Enter Phase 2 Clinical Study with GAL-101

Board consists of key opinion leaders from both clinical practice and academia with strong track records in the development of...

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

June 10, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial...

Presentation at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting Highlights Ashvattha Product Candidates for Neuroinflammation Imaging and Treatment

Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based...

error: Content is protected !!